Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5625531 | Alzheimer's & Dementia | 2006 | 4 Pages |
Abstract
The last 13 years have witnessed introduction of disease-modifying drugs (DMDT) in the multiple sclerosis (MS) field. This remarkable occurrence has not only ushered in an era of therapeutic optimism, it has stimulated change in how the pathogenesis of MS is viewed, how clinical studies should be conducted, and how outcome should be measured. These issues are in a stage of evolution at the time of this writing, but many have great relevance to development of DMDT in Alzheimer's disease (AD).
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Richard A. Rudick,